View ValuationPositron 将来の成長Future 基準チェック /06現在、 Positronの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Positron は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:POSC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20260-10-4-4N/A12/31/20250-11-5-5N/A9/30/20250-5-4-4N/A12/31/20241-2-2-2N/A12/31/20231-2-2-2N/A9/30/20151-1N/A-1N/A6/30/20151-2N/A-2N/Aアナリストによる今後の成長予測収入対貯蓄率: POSCの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: POSCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: POSCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: POSCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: POSCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: POSCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 08:26終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Positron Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.
お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.
お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.
お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts.